Patrick B. Lappin

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Kevin P. Baker, Bryan Edwards, Sarah Main et al. · Arthritis & Rheumatism · 2003 · 470 citations

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 456 citations · Full text

Drug Target, Health Sciences, Preclinical Models +10

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 267 citations · Full text

Inhibitory Activity, Radiation Oncology, Fusion Kinases +14

Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects

Wendy Halpern, Patrick B. Lappin, Thomas A. Zanardi et al. · Toxicological Sciences · 2006 · 148 citations

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Dana D. Hu‐Lowe, Enhong Chen, Lianglin Zhang et al. · Cancer Research · 2011 · 132 citations · Full text

Action Complementary, Immunology, Tumor Biology +16